Multicenter randomized controlled clinical study of allogeneic human umbilical cord mesenchymal stem cells in the treatment of hepatitis B-related acute-on-chronic liver failure

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030332

Enrollment

Unknown

Registered

2020-02-28

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-ACLF

Interventions

MSC group:MSC

Saline placebo control group:Saline

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients meet the criteria of ACLF, with 1-3 organ failure in six organs; 2. Aged between 18-70 years old; 3. Female subjects of childbearing age agree to use contraception throughout study period; 4. The subjects have no mental illness or language dysfunction, could understand the situation of this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients meet the criteria of ACLF, with over 3 organ failure in six organs; 2. With liver cancer or other malignancies; 3. Patients with severe chronic extrahepatic organ failure; 4. Pregnancy and lactation; 5. Patients use immunosuppressants, including glucocorticoids, for diseases other than the liver in the near future (within 1 year); 7. Other situations that the researchers think are not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
12 week mortality;	—

Secondary

Measure	Time frame
CLIF-ACLF score;	—

Countries

China

Contacts

Public ContactQi Zhang

The third affliated hospital of sun yat sen unniversity

zhangq27@mail.sysu.edu.cn+86 20-85253106

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026